Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 7 Ethyl 10 Hydroxycamptothecin
2. 7-ethyl-10-hydroxycamptothecin
3. Camptosar
4. Camptothecin 11
5. Camptothecin-11
6. Cpt 11
7. Cpt-11
8. Cpt11
9. Irinotecan
10. Irrinotecan
11. Nk012 Compound
12. Sn 38
13. Sn 38 11
14. Sn-38
15. Sn-38-11
16. Sn3811
1. 100286-90-6
2. Irinotecan Hcl
3. Topotecin
4. Campto
5. Camptothecin 11 Hydrochloride
6. Camptosar
7. Cpt 11
8. Cpt-11
9. Irinotecan (hydrochloride)
10. Camptothecin 11
11. U 101440e
12. Chebi:5971
13. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
14. Camptothecin Analog
15. 06x131e4oe
16. 7-ethyl-10-(4-(1-piperidino)-1-piperidino)carbonyloxy Camptothecin Hydrochloride
17. Nsc616348
18. Nsc-616348
19. Ncgc00095190-01
20. Dsstox_cid_25953
21. Dsstox_rid_81249
22. Dsstox_gsid_45953
23. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;hydrochloride
24. Irinotecan Hydrochloride Anhydrous
25. Cas-100286-90-6
26. U-101440e
27. Unii-06x131e4oe
28. Irinotecan Hydrochloride [usan:jan]
29. Mfcd01862255
30. Irinotecanhydrochloride
31. Cpt-11 Hydrochloride
32. Irinotecan Monohydrochloride
33. Schembl4033
34. Camptosar (tn) (pharmacia)
35. (s)-[1,4'-bipiperidine]-1'-carboxylic Acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester Hydrochloride
36. Spectrum1505821
37. Chembl541887
38. Dtxsid6045953
39. Hms1922j04
40. Pharmakon1600-01505821
41. Amy24895
42. Bcp17234
43. Irinotecan Hydrochloride (anhydrous)
44. Tox21_111479
45. Hy-16562a
46. Nsc759878
47. S5026
48. Akos015901921
49. Tox21_111479_1
50. Ccg-213561
51. Irinotecan Hydrochloride [who-dd]
52. Ncgc00095190-02
53. Ncgc00178697-04
54. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride
55. (1,4'-bipiperidine)-1'-carboxylic Acid, 3,4,12,14-tetrahydro-4,11-diethyl-4-hydroxy-3,4-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Monohydrochloride, (s)-
56. Ac-28335
57. As-13304
58. I0714
59. Irinotecan Hydrochloride Anhydrous [mi]
60. Irinotecan Hydrochloride, Topoisomerase Inhibitor
61. 286i906
62. A897508
63. Sr-01000763864
64. Q-100016
65. Sr-01000763864-3
66. Q27106952
67. Z1550648758
68. (+)-7-ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate, Monohydrochloride
69. (1,4'-bipiperidine)-1'-carboxylic Acid, (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl Ester, Hydrochloride (1:1)
70. (19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
71. (4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylic Acid Ester Hydrochloride
72. (4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate Hydrochloride
73. (s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl[1,4'-bipiperidine]-1'-carboxylatehydrochloride
74. [(19s)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate Hydrochloride
75. [1, 4,11-diethyl-3,4,12, 14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7] Indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride (s)-
76. [1,4'-bipiperidine]-1'-carboxylic Acid,(4s)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl Ester, Monohydrochloride
77. 1-[1-({[(4s)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl]oxy}carbonyl)piperidin-4-yl]piperidin-1-ium Chloride
1. Camptosar
2. Campto
3. Irinotecan
4. Hy-16562
Molecular Weight | 623.1 g/mol |
---|---|
Molecular Formula | C33H39ClN4O6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 622.2558127 g/mol |
Monoisotopic Mass | 622.2558127 g/mol |
Topological Polar Surface Area | 113 Ų |
Heavy Atom Count | 44 |
Formal Charge | 0 |
Complexity | 1200 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
2 of 2 | |
---|---|
Drug Name | Irinotecan hydrochloride |
Drug Label | Irinotecan hydrochloride injection is an antineoplastic agent of the topoisomerase I inhibitor class. Irinotecan hydrochloride was clinically investigated as CPT-11. Irinotecan hydrochloride injection is supplied as a sterile, pale yellow, clear, aqu... |
Active Ingredient | Irinotecan hydrochloride |
Dosage Form | Injectable |
Route | injection; Injection |
Strength | 20mg/ml; 100mg/5ml (20mg/ml); 500mg/25ml (20mg/ml); 100mg/5ml; 40mg/2ml (20mg/ml) |
Market Status | Prescription |
Company | Pliva Lachema; Hospira; Teva Parenteral; Fresenius Kabi Oncol; Accord Hlthcare; Jiangsu Hengrui Med; Hikma Farmaceutica; Teva Pharms Usa; Cipla; Hisun Pharm Hangzhou; Sun Pharma Global; Actavis Elizabeth; Emcure Pharms; Mustafa Nevzat Ilac; Fresenius Kabi |
Topoisomerase I Inhibitors
Compounds that inhibit the activity of DNA TOPOISOMERASE I. (See all compounds classified as Topoisomerase I Inhibitors.)
Irinotecan Hydrochloride Trihydrate
Date of Issue : 2022-11-09
Valid Till : 2025-08-08
Written Confirmation Number : WC-0138
Address of the Firm : Plot No. 285, 286 & 287, Bommasandra-Jigani Link Road, Industrial Area, KIADB, 4...
Irinotecan Hydrochloride (USP)
Date of Issue : 2019-10-07
Valid Till : 2022-07-02
Written Confirmation Number : WC-0226
Address of the Firm : D-24 and D24/1 MIDC Kurkumbh Tal. Daund, Dist Pune 413 802, Maharashtra State
Irinotecan Hydrochloride Trihydrate (USP)
Date of Issue : 2019-07-08
Valid Till : 2022-07-07
Written Confirmation Number : WC-0115
Address of the Firm : D-35, Industrial Area, Kalyani, Dist Nadia-741 235, West Bengal
Date of Issue : 2022-09-16
Valid Till : 2025-08-08
Written Confirmation Number : WC-0041
Address of the Firm : Unit-I, Survey No.10, I.D.A, Gaddapotharam Village, Jinnaram Mandal,Medak Dist, ...
Irinotecan Hydrochloride Trihydrate (USP/IH)
Date of Issue : 2023-07-03
Valid Till : 2025-07-02
Written Confirmation Number : WC-0213
Address of the Firm : Plot No.21, Jawaharlal Nehru Pharma City, Parawada MandaI, Visakhapatnam, Visakh...
Date of Issue : 2021-01-22
Valid Till : 2023-08-01
Written Confirmation Number : WC-0275
Address of the Firm : N-211/2/10, MIDC, Boisar, Dist-Thane-401506, Mahrashtra
Irinotecan Hydrochloride Trihydrate (USP)
Date of Issue : 2019-07-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0148
Address of the Firm : # 1A & 1A ‘P’, 2,2A, 2B, 3A to 3E, 4A, 5A, 4B, & 5B, Deosugur Industrial Are...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
58
PharmaCompass offers a list of Irinotecan Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Irinotecan Hydrochloride manufacturer or Irinotecan Hydrochloride supplier.
PharmaCompass also assists you with knowing the Irinotecan Hydrochloride API Price utilized in the formulation of products. Irinotecan Hydrochloride API Price is not always fixed or binding as the Irinotecan Hydrochloride Price is obtained through a variety of data sources. The Irinotecan Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Irinotecan Hydrochloride Trihydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Irinotecan Hydrochloride Trihydrate, including repackagers and relabelers. The FDA regulates Irinotecan Hydrochloride Trihydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Irinotecan Hydrochloride Trihydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Irinotecan Hydrochloride Trihydrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Irinotecan Hydrochloride Trihydrate supplier is an individual or a company that provides Irinotecan Hydrochloride Trihydrate active pharmaceutical ingredient (API) or Irinotecan Hydrochloride Trihydrate finished formulations upon request. The Irinotecan Hydrochloride Trihydrate suppliers may include Irinotecan Hydrochloride Trihydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Irinotecan Hydrochloride Trihydrate DMF (Drug Master File) is a document detailing the whole manufacturing process of Irinotecan Hydrochloride Trihydrate active pharmaceutical ingredient (API) in detail. Different forms of Irinotecan Hydrochloride Trihydrate DMFs exist exist since differing nations have different regulations, such as Irinotecan Hydrochloride Trihydrate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Irinotecan Hydrochloride Trihydrate DMF submitted to regulatory agencies in the US is known as a USDMF. Irinotecan Hydrochloride Trihydrate USDMF includes data on Irinotecan Hydrochloride Trihydrate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Irinotecan Hydrochloride Trihydrate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Irinotecan Hydrochloride Trihydrate Drug Master File in Japan (Irinotecan Hydrochloride Trihydrate JDMF) empowers Irinotecan Hydrochloride Trihydrate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Irinotecan Hydrochloride Trihydrate JDMF during the approval evaluation for pharmaceutical products. At the time of Irinotecan Hydrochloride Trihydrate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Irinotecan Hydrochloride Trihydrate Drug Master File in Korea (Irinotecan Hydrochloride Trihydrate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Irinotecan Hydrochloride Trihydrate. The MFDS reviews the Irinotecan Hydrochloride Trihydrate KDMF as part of the drug registration process and uses the information provided in the Irinotecan Hydrochloride Trihydrate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Irinotecan Hydrochloride Trihydrate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Irinotecan Hydrochloride Trihydrate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with KDMF on PharmaCompass.
A Irinotecan Hydrochloride Trihydrate CEP of the European Pharmacopoeia monograph is often referred to as a Irinotecan Hydrochloride Trihydrate Certificate of Suitability (COS). The purpose of a Irinotecan Hydrochloride Trihydrate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Irinotecan Hydrochloride Trihydrate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Irinotecan Hydrochloride Trihydrate to their clients by showing that a Irinotecan Hydrochloride Trihydrate CEP has been issued for it. The manufacturer submits a Irinotecan Hydrochloride Trihydrate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Irinotecan Hydrochloride Trihydrate CEP holder for the record. Additionally, the data presented in the Irinotecan Hydrochloride Trihydrate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Irinotecan Hydrochloride Trihydrate DMF.
A Irinotecan Hydrochloride Trihydrate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Irinotecan Hydrochloride Trihydrate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with CEP (COS) on PharmaCompass.
A Irinotecan Hydrochloride Trihydrate written confirmation (Irinotecan Hydrochloride Trihydrate WC) is an official document issued by a regulatory agency to a Irinotecan Hydrochloride Trihydrate manufacturer, verifying that the manufacturing facility of a Irinotecan Hydrochloride Trihydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Irinotecan Hydrochloride Trihydrate APIs or Irinotecan Hydrochloride Trihydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Irinotecan Hydrochloride Trihydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Irinotecan Hydrochloride Trihydrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Irinotecan Hydrochloride Trihydrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Irinotecan Hydrochloride Trihydrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Irinotecan Hydrochloride Trihydrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Irinotecan Hydrochloride Trihydrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Irinotecan Hydrochloride Trihydrate suppliers with NDC on PharmaCompass.
Irinotecan Hydrochloride Trihydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Irinotecan Hydrochloride Trihydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Irinotecan Hydrochloride Trihydrate GMP manufacturer or Irinotecan Hydrochloride Trihydrate GMP API supplier for your needs.
A Irinotecan Hydrochloride Trihydrate CoA (Certificate of Analysis) is a formal document that attests to Irinotecan Hydrochloride Trihydrate's compliance with Irinotecan Hydrochloride Trihydrate specifications and serves as a tool for batch-level quality control.
Irinotecan Hydrochloride Trihydrate CoA mostly includes findings from lab analyses of a specific batch. For each Irinotecan Hydrochloride Trihydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Irinotecan Hydrochloride Trihydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Irinotecan Hydrochloride Trihydrate EP), Irinotecan Hydrochloride Trihydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Irinotecan Hydrochloride Trihydrate USP).